Find Academic Supervisors

Muhannad M. AlsyoufView profile

Assistant Professor

• Urology
• Testicular Cancer
• Bladder Cancer
• +6 more

Muhannad M. Alsyouf, MD is an Assistant Professor in the Department of Urology at Loma Linda University School of Medicine. His clinical and research focus centers on urological oncology with particular expertise in testicular cancer, bladder cancer, and minimally invasive surgical techniques. Dr. Alsyouf maintains active research programs investigating novel diagnostic approaches for germ cell tumors and optimizing surgical outcomes in urological cancer patients. Dr. Alsyouf's research interests span multiple critical areas in modern urology including biomarker development for early cancer detection, surgical technique optimization, and quality improvement in urological care. His work on miRNA biomarkers for germ cell tumors represents a significant advancement in non-invasive cancer detection. He has substantial expertise in retroperitoneal lymph node dissection techniques and has published extensively on outcomes related to this complex surgical procedure. His research also addresses important clinical issues such as opioid stewardship following urological cancer surgery and the impact of surgical techniques on patient recovery. Analysis of Dr. Alsyouf's recent publications reveals a strong emphasis on testicular cancer management, particularly the use of novel biomarkers like miRNA-371 for detecting active germ cell tumors. His work on the MAGESTIC Trial represents a significant contribution to the field. He also maintains active research programs in bladder cancer outcomes, kidney stone management, and surgical technique optimization. His publications demonstrate a consistent focus on improving diagnostic accuracy and surgical outcomes while reducing patient morbidity. Dr. Alsyouf serves as Principal Investigator or Co-Investigator on numerous active research projects, including the MAGESTIC Trial investigating serum Micro RNA-371 for detecting active germ cell tumors, multiple studies on bladder cancer management, and various projects examining surgical techniques in stone disease. His research portfolio demonstrates strong institutional support with funding from both internal university sources and external industry partners. As an active member of the urology research community, Dr. Alsyouf has contributed significantly to advancing knowledge in urological oncology through his extensive publication record and ongoing clinical investigations. His work bridges the gap between basic science discoveries and clinical applications, with particular attention to improving diagnostic accuracy and surgical outcomes for patients with urological malignancies.

Joseph MerolaView profile

Professor

• Organometallic Chemistry
• Catalysis
• Antimicrobial Agents
• +5 more

Joseph Merola is a Professor of Chemistry at Virginia Polytechnic Institute & State University (Virginia Tech), with a joint appointment in the Faculty of Health Sciences . He is a Fellow of both the American Chemical Society (ACS) and the American Association for the Advancement of Science (AAAS). Education: B.S. from Carnegie-Mellon University (1974), Ph.D. from MIT (1978). Career: Joined Virginia Tech in 1987 after a 9-year industrial research career at Exxon. Promoted to full professor in 1995. Held administrative roles including Associate Dean (1998-2001) and Department Chair (2004-2010). Research Interests: Focus on organometallic chemistry bridging inorganic and organic disciplines. Key areas include: Catalysis: Designing iridium, rhodium, and palladium complexes for asymmetric transfer hydrogenation (ATH) of aryl ketones, producing chiral alcohols for pharmaceuticals. Biological Activity: Discovering antimicrobial and antiviral properties in noble metal complexes, particularly against MRSA, TB, and SARS-CoV-2. Collaborations with Prof. Joe Falkinham (Biological Sciences) and James Weger-Lucarelli (Biomedical Sciences). Cluster Chemistry: Synthesizing unusual metal clusters like octametallic iridium systems and Ir3Na1O4 cubane structures. Publication Trends: Recent work emphasizes dual functionality of organometallic systems in catalysis and biological applications. Collaboration-driven research with interdisciplinary implications for drug discovery and sustainable catalysis. Scientific Awards: 24 radio interviews on AAAS Science Update (1997-2021) Microsoft Technology Tools for Today’s Campuses (2007) ACS Omega Molecule of the Week (2020) Multiple Virginia Tech teaching excellence awards (1991-2019) Fellowships from AAAS (2015) and ACS (2019) Advising and Leadership: Mentored numerous graduate and undergraduate researchers. Advocates for personalized teaching approaches, technology integration, and public science communication through Scientific American and radio programs. Led departmental and graduate school administrative initiatives.

Tom BlundellView profile

Professor

• Structural biology
• Structural bioinformatics
• Drug discovery
• +6 more

Sir Tom Blundell is Emeritus Professor and Director of Research in the Department of Biochemistry, University of Cambridge, where he has held the Sir William Dunn Professorship since 1995. He is also Emeritus Fellow at a Cambridge college and co-founder of Astex Therapeutics. A Fellow of the Royal Society, the Academy of Medical Sciences and Academia Europaea, he has received honorary doctorates from fifteen universities. Education and academic career: Professor of Crystallography, Birkbeck College, University of London (1976) Honorary Director, Imperial Cancer Research Fund Unit of Structural Molecular Biology (1989) Sir William Dunn Professor of Biochemistry, University of Cambridge (1995–present) Chairman, Council of Biological Sciences, University of Cambridge (from 2003) Research interests: Tom Blundell’s research integrates structural biology and computational chemistry to understand multiprotein assemblies that control cell regulation, DNA repair, and mitosis. His group uses X-ray crystallography and cryo-electron microscopy to resolve macromolecular structures, then applies structure-guided fragment-based discovery to develop chemical probes and therapeutics against cancer and mycobacterial infections . Recent work focuses on DNA-PKcs in non-homologous end joining , anti-tuberculosis inhibitors , and SARS-CoV-2 targets . Scientific awards and honours: Fellow of the Royal Society (FRS) Fellow of the Academy of Medical Sciences (FMedSci) Member of Academia Europaea Honorary doctorates from fifteen universities worldwide Leadership, boards and grants: Director-General, Agricultural and Food Research Council (1991–1994) Founding Chief Executive, Biotechnology and Biological Sciences Research Council (BBSRC) (1994–1996) Chairman, Royal Commission on Environmental Pollution (1998–2005) President, UK Biosciences Federation (2004–2008) Co-founder and SAB member, Astex Therapeutics (oncology drugs in early clinical trials) Non-Executive Director, Celltech (1996–2005) Science advisory roles with Pfizer, UCB, SmithKline Beecham Labs, teams and resources: Blundell directs an interdisciplinary research group housed in the Department of Biochemistry, Cambridge, with access to world-class synchrotron and cryo-EM facilities. The team combines wet-lab structural biology with computational platforms such as PDBe-KB , ProtCHOIR , Graphein and SDM for structural bioinformatics and AI-driven drug discovery.

• Epidemiology
• Health economics
• Infectious diseases
• +4 more

David Boettiger is a Conjoint Associate Professor at the University of Newcastle's School of Medicine and Public Health, where he applies expertise in epidemiology and health economics to address global infectious disease challenges. His research on HIV and viral hepatitis has directly influenced clinical guidelines in Australia and internationally, improving health outcomes for affected populations. As the research lead for FluTracking, Australia's only community-level respiratory infection surveillance system, he plays a critical role in the National Influenza Surveillance Program. Dr. Boettiger holds a Doctor of Philosophy from the University of New South Wales, alongside a Bachelor of Biomedical Science and Master of Pharmacy from the University of Newcastle. His educational background in both clinical and research disciplines informs his interdisciplinary approach to public health challenges. His primary research interests span infectious disease epidemiology, health economics, and public health policy, with particular focus on HIV, viral hepatitis, respiratory viruses, and antimicrobial resistance. Through advanced analysis of large datasets and quantitative modeling, his work addresses critical questions in disease prevention, detection, and management across diverse global contexts including Australia, Thailand, Mali, and Indonesia. Analysis of Dr. Boettiger's recent publications reveals a strong emphasis on practical public health applications, with research spanning HIV treatment optimization, pandemic response strategies, antimicrobial stewardship, and innovative disease surveillance approaches. His work consistently bridges epidemiological research with health economic evaluation, providing evidence for policymakers on cost-effective interventions. Dr. Boettiger has secured significant research funding as Chief Investigator on NHMRC and UK-MRC grants totaling over $7.1 million, demonstrating the impact and relevance of his work to national and international health priorities. His FluTracking initiative represents a major contribution to Australia's public health infrastructure for monitoring respiratory infections at the community level. As research lead for FluTracking, Dr. Boettiger oversees a team that integrates data from multiple surveillance systems, cohort studies, and clinical trials to evaluate the population impact of respiratory viruses and assess the effectiveness of public health measures. His collaborative approach brings together clinical, laboratory, and public health experts to advance the goal of creating a world where respiratory infections are rare, rapidly diagnosed, and easily treated.

• Bayesian Statistics
• Neuroscience
• Healthcare Statistics
• +5 more

Nicolo Margaritella is a Lecturer in Statistics at the School of Mathematics and Statistics, University of St Andrews. His academic profile demonstrates active engagement in statistical methodology development with applications in neuroscience and healthcare. His research interests center on Bayesian statistics, particularly the analysis of complex spatio-temporal data and large-scale inference problems. His work has significant applications in neuroscience (focusing on functional magnetic resonance imaging and electroencephalogram data analysis) and healthcare (particularly in tuberculosis diagnostics and multiple sclerosis research). Margaritella's recent publications demonstrate expertise in functional principal component analysis, Bayesian false discovery rate methods, and power function applications. His work bridges theoretical statistical methodology with practical healthcare applications, contributing to UN Sustainable Development Goals related to health and well-being. Scientific Recognition: Associate Fellow of the Higher Education Academy (AFHEA) (2018) Research Funding: Principal Investigator for London Mathematical Society (LMS) Research in Pairs Grant (2022) Principal Investigator for London Mathematical Society (LMS) Early Career Fellowship (2020-2021) Margaritella has developed the APFr R package for multiple testing approaches and has been active in presenting his work through public lectures on advanced Bayesian methods for neuroscientific data analysis.

• Strategic Management
• Social and Health Marketing
• Integrated Care
• +9 more

Prof. Todorka Ignatova Kostadinova is a Professor in the Department of Health Economics and Management at the Faculty of Public Health, Medical University of Varna. She has held significant administrative roles including Dean of the Faculty of Public Health (2011-2012), Vice Rector for International Cooperation (2012-2020), and currently serves as Director of International Cooperation, Accreditation and Quality Directorate since 2020. Her career uniquely bridges academic leadership, government service as Parliamentary Secretary and Deputy Minister of Health (2009-2010), and international health policy collaboration with organizations like the Global Fund and EU networks. Education: Two Master's Degrees in Economics and Pedagogy from University of Economics–Varna Doctoral degree in Economics from University of National and World Economy (UNWE)–Sofia (2001) on "Portfolio Management Potentials of Medical Establishments" Research Interests: Prof. Kostadinova's work centers on Strategic Management and Health Economics with specialized focus on Social and Health Marketing, Integrated Care systems, and Risk Management in healthcare. Her research integrates Social Entrepreneurship and Innovation frameworks with practical applications in Medical Informatics and Health Management, addressing challenges in public health systems transformation and international project implementation across Europe and the Balkans. Scientific Awards: No specific awards documented in source material Advising and Grants: She supervises 15 PhD students (10 graduated, 5 ongoing) and has led major international initiatives including Global Fund programs for AIDS/Malaria/Tuberculosis, EU health workforce projects, and eHealth implementations. Her grant portfolio spans collaborations with Berkeley University's Global Health Leadership Forum, WHO networks, and European Commission frameworks. Labs and Teams: Prof. Kostadinova co-founded the International Society of Integrated Care research consortium and led Medical University of Varna's delegation in the EU Health Workforce Network. She established cross-border teams for the South-East Europe Health Network and directs the university's International Cooperation Directorate coordinating 12 active EU-funded health projects.

Augustine M. ManadanView profile

Professor

• Rheumatology
• Internal Medicine
• Autoimmune Diseases
• +3 more

Augustine M. Manadan, MD is a Professor in the Department of Internal Medicine at Rush Medical College , with a focus on rheumatology and autoimmune diseases. He serves as Fellowship Program Director and Program Director for Rush Rheumatology. Clinical expertise: Ankylosing spondylitis, Lupus, Rheumatoid arthritis, Sjogren's syndrome, and other inflammatory conditions Primary location: Rush Rheumatology - Orthopedic Building (Chicago, IL) Research Interests span autoimmune/myoinflammatory disorders, infectious disease interactions in rheumatology, and dual antiplatelet therapy risks. His work includes nationwide epidemiological studies on rare conditions like Still's disease and dermatomyositis. Scientific Contributions include co-authoring the POINT Trial (NCT00991029) on clopidogrel-aspirin combinations post-stroke, revealing conflicting efficacy/safety profiles. His recent 2024 studies examine neuromyelitis optica in lupus/Sjogren's patients and hemophagocytic lymphohistiocytosis in Still's disease. Publications (>60 total) focus on: Antiplatelet therapy complications (2013-2024) Autoimmune comorbidities (2006-2024) Infectious risks in immunosuppressed patients (2006-2017) Readmission patterns in inflammatory myopathies (2023)

Kudakwashe ChaniView profile

Researcher

• Health Systems Research
• Public Health Policy
• Infectious Diseases
• +7 more

Kudakwashe Chani is a PhD candidate at the National Centre for Epidemiology and Population Health (NCEPH) within the Australian National University (ANU). His research focuses on the impact of decentralizing rapid molecular tests for TB and MDR-TB care in Zimbabwe. Education: Master of Public Health (University of South Africa), Bachelor of Medicine and Surgery (University of Zimbabwe) Experience: Over 25 years in clinical medicine and public health program design across southern Africa and the Pacific Dr. Chani's research spans health systems and policy , with expertise in tuberculosis (including drug-resistant TB) , HIV , antimicrobial resistance (AMR) , and One Health . His work has addressed MDR-TB contact screening in Papua New Guinea, TB mortality diagnostics, treatment delays in Australia, and staff turnover in Namibia. Publications highlight interdisciplinary approaches to infectious disease control and health systems strengthening. Current Affiliations: Student, National Centre for Epidemiology and Population Health Student, Department of Applied Epidemiology Member, Infectious Diseases and Modelling Group His research integrates global health challenges with empirical analysis, focusing on low-resource settings and policy-relevant outcomes.

Samuel VidalView profile

Lecturer

• Infectious Diseases
• Vaccine Development
• Tuberculosis
• +2 more

Samuel Vidal, M.D., Ph.D., serves as an Instructor in Medicine at Harvard Medical School, an infectious diseases physician at Brigham and Women’s Hospital, and a Staff Scientist in the Barouch laboratory at the Center for Virology and Vaccine Research. His clinical responsibilities encompass inpatient and outpatient infectious diseases services at Brigham and Women’s Hospital, integrating direct patient care with translational research. Dr. Vidal's educational journey includes: B.A. in Biochemistry from Haverford College Concurrent M.D. and Ph.D. degrees from Columbia University's Medical Scientist Training Program Internal Medicine internship and residency at New York Presbyterian Hospital Columbia campus Infectious Diseases subspecialty training at Massachusetts General Hospital and Brigham and Women’s Hospital NIH T32 postdoctoral research fellowship in the Barouch laboratory His research program centers on pioneering antigen-based and live-attenuated tuberculosis vaccines, operating at the critical intersection of virology, immunology, and infectious disease pathogenesis. This work leverages the Barouch laboratory's expertise in viral vector platforms to address global tuberculosis challenges through novel vaccine design and efficacy evaluation. As leader of the tuberculosis vaccine development team within the Center for Virology and Vaccine Research, Dr. Vidal mentors junior scientists and coordinates preclinical research activities. While specific grant mechanisms aren't detailed, his NIH T32 fellowship background suggests strong federal research training foundations. The Barouch laboratory provides the primary research ecosystem for Dr. Vidal's work, situated within Harvard Medical School's Department of Medicine and affiliated with Brigham and Women’s Hospital. This environment enables direct translation of vaccine discoveries from bench to clinical application through hospital-based infectious diseases expertise.

• Disaster Medicine
• Humanitarian Health Ethics
• Refugee and Immigrant Health
• +3 more

Lynda Redwood-Campbell is a Professor in the Department of Family Medicine at McMaster University and an active member of the Canadian Red Cross International Emergency Response. Her work bridges family medicine with humanitarian health ethics, disaster response, and global primary care development. Research Interests: Disaster Medicine and Emergency Response Humanitarian Health Ethics Palliative Care in Resource-Limited Settings Refugee and Immigrant Health Global Family Medicine Education Article Trends: Her 15 most recent publications focus on disaster response strategies (2018-2023), ethical challenges in humanitarian aid (2012-2018), refugee health (2009-2018), and global health education (2015-2017). Key journals include Prehospital and Disaster Medicine , Canadian Family Physician , and Public Health Ethics . Scientific Context: Her work spans public health, disaster medicine, and global health education, with emphasis on knowledge transfer from international deployments to domestic preparedness, ethical frameworks for humanitarian care, and strengthening primary care in low-resource settings.

Nevan KroganView profile

Professor

• Proteomics
• Genetics
• Cancer Biology
• +4 more

Nevan Krogan is a Professor at the University of California San Francisco (UCSF), where he leads the Krogan Lab. His research focuses on developing systematic proteomic and genetic approaches to study complex biological problems in cancer , infectious diseases , and psychiatric disorders . He serves as Principal or Co-Principal Investigator on multiple NIH-funded grants, including programs on HIV, TB, and SARS-CoV-2. Education BS in Chemistry, University of Regina (1997) MSc in Biochemistry, University of Regina (1999) PhD in Medical Genetics, University of Toronto (2005) Research Focus Krogan's lab integrates proteomics, genetics, and systems biology to analyze: Host-pathogen interactions in HIV, Ebola, and coronaviruses Protein interaction networks in cancer systems biology Neurodegenerative mechanisms linked to apoE4 and tau CRISPR-based functional genomics in stem cells Antiviral therapeutic targets like Mac1 hydrolase Scientific Awards Alumni Crowning Achievement Award, University of Regina (2014) Keck Distinguished Young Scholar (2012) Searle Scholar (2009-2014) Top 25 authors in molecular biology & genetics (2002-2006) Grants & Collaborations Krogan leads the QCRG Pandemic Response Program and Cancer Cell Map Initiative v2.0 , both NIH-funded. He co-leads the Host-Pathogen Mapping Initiative and HARC Center , while collaborating on projects related to influenza, dengue, and tuberculosis.

• Public Health
• Global Health
• Tuberculosis Research
• +4 more

Nirmal Ahuja serves as an Assistant Professor of Biobehavioral Health within the School of Behavioral Sciences and Education at Pennsylvania State University's Harrisburg campus. He maintains a dual affiliation with the Penn State Cancer Institute, specifically contributing to cancer control initiatives through interdisciplinary research and policy engagement. His research program bridges global and domestic public health challenges, with concentrated expertise in tuberculosis management in Western India and cancer care navigation within Pennsylvania's healthcare system. Key investigations examine how social support networks influence tuberculosis medication adherence, patient preferences for inhalant-based treatments, and systemic barriers affecting U.S. adults' willingness to disclose social needs to healthcare providers. This work consistently addresses UN Sustainable Development Goals related to health equity and quality healthcare access, employing mixed-methods approaches that integrate qualitative insights with policy analysis. Analysis of his 2020-2025 publications reveals a cohesive trajectory examining patient experiences across diverse health conditions and geographic contexts. His scholarship demonstrates particular strength in translating research findings into actionable policy solutions, as evidenced by significant news coverage and academic engagement with his work on cancer care navigation in Pennsylvania. Scientific Awards: No specific awards, fellowships, or medals are documented in available sources. Regarding academic mentorship, the provided materials contain no details about graduate students supervised or postdoctoral researchers mentored. Similarly, no information is available regarding research grants secured as principal investigator or collaborative funding mechanisms supporting his work. Dr. Ahuja operates within expansive collaborative networks, engaging with the Penn State Cancer Institute's multidisciplinary teams and international partners in India. His projects routinely involve healthcare professionals, policy analysts, and community stakeholders to develop context-specific interventions addressing complex public health challenges in both resource-limited and developed settings.

• Infectious Diseases
• Public Health
• Global Health
• +7 more

Stephen Symes is a Clinical Associate Professor of Medicine specializing in Infectious Diseases . His work focuses on global health, mental health, and public health aspects of marginalized populations, including asylum seekers and survivors of human trafficking. Education: MD from Howard University College of Medicine (1989) Research Interests: Dr. Symes investigates health disparities and systemic challenges in treating vulnerable groups. His studies span Infectious Diseases (e.g., HIV, tuberculosis), Sleep Medicine , LGBTQ Health , and Medical Education , often employing multidisciplinary approaches. Publication Trends: His recent articles (2015–2021) emphasize Global Health , Public Health , and Social Medicine , with a focus on Human Trafficking , Asylum Seekers , and Health Equity . Labs/Teams: He collaborates with multidisciplinary clinics like the THRIVE Clinic , addressing healthcare for survivors of human trafficking.

Ciaran SkerryView profile

Assistant Professor

• Microbiology
• Immunology
• Bacterial Pathogenesis
• +4 more

Ciaran Skerry, PhD, serves as an Assistant Professor in the Department of Microbiology and Immunology at the University of Maryland School of Medicine. His research bridges bacterial pathogenesis and host-directed therapeutics, with dual expertise in tuberculosis and pertussis developed through foundational work at Johns Hopkins University and the University of Maryland. His academic journey reflects deep specialization in translating basic discoveries into novel interventions for antibiotic-resistant infections. Dr. Skerry's educational background includes: B.Sc in Biotechnology, National University of Ireland, Maynooth (2006) Ph.D in Immunology, National University of Ireland, Maynooth (2010) Postdoctoral Fellowship in Microbiology, Johns Hopkins University School of Medicine (2014) Postdoctoral Fellowship in Micro/Immunology, University of Maryland School of Medicine (2017) His research program centers on host-pathogen interactions, with three major pillars: 1) Development of live attenuated pertussis vaccines including the BPZE1 strain; 2) Molecular characterization of TB granulomas using nuclear imaging techniques; 3) Pioneering host-directed therapies targeting sphingosine-1-phosphate signaling for pertussis and statin-based approaches for tuberculosis. His current work focuses on peptidoglycan recognition protein 4 (PGLYRP4) as a critical mediator in inflammation control during Bordetella infection. Analysis of his 13 most recent publications (2009-2017) reveals a strategic evolution from vaccine development toward host-directed therapeutics. Over 70% of his work since 2015 focuses on sphingosine-1-phosphate receptor modulation for pertussis, while earlier tuberculosis research established foundational models for hypoxic granuloma studies. His publications consistently appear in high-impact infectious disease journals including Journal of Infectious Diseases and PLoS One, demonstrating translational impact across both bacterial pathogens. Scientific awards and honors include: John and Pat Hume Research Scholarship (2006-2010) Irish Research Council for Science Engineering and Technology Scholarship (2006-2010) Dr. Skerry has not secured major research funding in the past three years according to his biographical documentation. While his faculty position suggests graduate student mentorship responsibilities, no specific advisees are documented in the provided materials. His professional memberships include the American Society for Microbiology and International Bordetella Society. He leads an active research laboratory within the University of Maryland's Department of Microbiology and Immunology, where his team utilizes advanced murine models to investigate S1P receptor agonists and PGLYRP4 biology. The lab's current focus on mechanistic studies of host-directed therapeutics positions them at the forefront of developing alternatives to conventional antibiotics for bacterial respiratory pathogens.

• Wildlife Conservation
• Ecology
• Environmental Policy
• +3 more

Brent Rudolph is an Adjunct Assistant Professor in the Department of Fisheries and Wildlife at the College of Agriculture & Natural Resources, and the Director of Sustainability Partnerships for Pheasants Forever and Quail Forever (PF&QF). In his roles, he develops collaborative grassland and farmland conservation programs aligned with environmental, social, and economic sustainability goals, partnering with organizations, corporations, and foundations. Ph.D. in Fisheries and Wildlife , Michigan State University M.S. in Environmental and Forest Biology , SUNY College of Environmental Science and Forestry B.S. in Biology , Ohio Northern University His research focuses on integrating insights from social sciences and wildlife ecology, particularly examining factors affecting hunters’ trust in agencies and compliance with conservation policies such as bovine tuberculosis eradication. Prior to PF&QF, he coordinated policy and hunting regulations for the Michigan Department of Natural Resources (MDNR) and oversaw research partnerships with Michigan State University. As an educator, Rudolph contributes to wildlife conservation training and policy development, though no formal advisees or awards are listed in the provided text. His work emphasizes stakeholder engagement and interdisciplinary approaches to managing ecosystems.